Drug Trial Radar · NCT00423657
Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections
Last checked: Nov 19, 2026Latest source record: Mar 14, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
680
Actual
Start
Mar 2007
Primary completion
Dec 2007
Study completion Dec 2007
Sponsor
- Lead sponsor
- Forest LaboratoriesAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Jan 18, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether ceftaroline is effective and safe in the treatment of complicated skin infections in adults.
Conditions
- Bacterial Infections
Interventions
ceftarolineDrug
600 mg parenteral infused over 60 minutes, every 12 hours for 5 to 14 days
vancomycin plus aztreonamDrug
vancomycin at 1 g parenteral infused over 60 minutes followed by aztreonam 1 g infused over 60 minutes, every 12 hours, for 5 to 14 days.
PlaceboDrug
Ceftaroline fosamil 600 mg administered intravenously over 60 minutes every 12 hours, followed by placebo administered over 60 minutes every 12 hours.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Cure Rate at Test of Cure (TOC) (MITT Population)Time frame: 8-15 days after last dose of study drug administration
- The Primary Efficacy Outcome Measure Was the Per-subject Clinical Cure Rate at the TOC Visit in the Clinically Evaluable (CE) Populations.Time frame: 8-15 days after last dose of study drug
Locations
54 sites in 12 countries. Site status is shown where the registry gives one.
Investigational Site
Buena Park, California
Investigational Site
Hawaiian Gardens, California
Investigational Site
Los Angeles, California
Investigational Site
Pasadena, California
Investigational Site
San Diego, California
Investigational Site
San Jose, California
Investigational Site
Atlantis, Florida
Investigational Site
Columbus, Georgia
Investigational Site
Marietta, Georgia
Investigational Site
Springfield, Illinois
Investigational Site
Baltimore, Maryland
Investigational Site
Minneapolis, Minnesota
Investigational Site
Butte, Montana
Investigational Site
Somers Point, New Jersey
Investigational Site
Toledo, Ohio
Investigational Site
Tacoma, Washington
Investigational Site
Milwaukee, Wisconsin
Investigational Site
Buenos Aires, Argentina
Investigational Site
Córdoba, Argentina
Investigational Site
Santa Fe, Argentina
Investigational Site
Braunau am Inn, Austria
Investigational Site
Graz, Austria
Investigational Site
Sankt Pölten, Austria
Investigational Site
Sao Paula, Brazil
Investigational Site
Temuco, Chile
Investigational Site
Valdivia, Chile
Investigational Site
Cottbus, Germany
Investigational Site
Dortmund, Germany
Investigational Site
Homburg/Saar, Germany
Investigational Site
Mainz, Germany
Investigational Site
Wiesbaden, Germany
Investigational Site
Riga, Latvia
Investigational Site
Guadalajara, Jalisco, Mexico
Investigational Site
Seattle Zapopan, Jalisco, Mexico
Investigational Site
Bielsko-Biala, Poland
Investigational Site
Krakow, Poland
Investigational Site
Krakow, Poland
Investigational Site
Lodz, Poland
Investigational Site
Lublin, Poland
Investigational Site
Poznan, Poland
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.